Rhythm Pharmaceuticals (RYTM) Misses Q2 EPS by 2c
Tweet
Share
E-mail
Get Alerts RYTM Hot Sheet
Join SI Premium – FREE
(Updated - August 1, 2023 11:16 AM EDT)
Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q2 EPS of ($0.82), $0.02 worse than the analyst estimate of ($0.80). Revenue for the quarter came in at $19.2 million versus the consensus estimate of $14.8 million.
For earnings history and earnings-related data on Rhythm Pharmaceuticals (RYTM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citizens launches transportation coverage, names FedEx a top large-cap pick
- SK Hynix vs. Micron deep dive: who wins the AI memory supercycle?
- Morgan Stanley stays bullish on aerospace, defense ahead of Q2 earnings
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
